Merck & Co. MRK Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $16.29B-0.7% | $16.4B-5.1% | $17.28B+9.3% | $15.81B+1.8% | $15.53B-0.6% | ||
| $4.2B-24.4% | $5.55B+44.0% | $3.86B+8.4% | $3.56B+4.0% | $3.42B-10.7% | ||
| $12.09B+11.4% | $10.85B-19.2% | $13.42B+9.6% | $12.25B+1.1% | $12.11B+2.7% | ||
| 74.2%+8.1pp | 66.2%-11.5pp | 77.7%+0.2pp | 77.5%-0.5pp | 78%+2.5pp | ||
| $12.59B+224% | $3.89B-8.2% | $4.23B+4.6% | $4.05B+11.8% | $3.62B-21.0% | ||
| $2.7B-6.8% | $2.9B+10.1% | $2.63B-0.6% | $2.65B+3.8% | $2.55B-10.9% | ||
| $195M-8.5% | $213M+353% | $47M-91.6% | $560M+712% | $69M+35.3% | ||
| -$3.53B-203% | $3.42B-49.3% | $6.75B+34.9% | $5B-15.3% | $5.9B+41.6% | ||
| $709M+54.8% | $458M-52.2% | $958M+67.8% | $571M-30.2% | $818M+92.0% | ||
| -$4.24B-243% | $2.96B-48.8% | $5.79B+30.7% | $4.43B-12.8% | $5.08B+35.7% | ||
| -26%-44.1pp | 18.1%-15.4pp | 33.5%+5.5pp | 28%-4.7pp | 32.7%+8.7pp | ||
| -$1.72-243% | $1.20-48.3% | $2.32+31.8% | $1.76-12.4% | $2.01+35.8% | ||
| -$1.72-242% | $1.21-47.8% | $2.32+31.8% | $1.76-12.4% | $2.01+35.8% | ||
| $19.82B+52.7% | $12.98B+23.3% | $10.53B-2.6% | $10.81B+12.3% | $9.63B-16.0% | ||
| -$138M+68.1% | -$432M-282% | $238M+3,300% | $7M-80.0% | $35M— | ||
| -$2.95B-160% | $4.91B-32.5% | $7.28B+31.9% | $5.52B-13.9% | $6.41B+36.5% | ||
| -18.1%-48.1pp | 30%-12.2pp | 42.1%+7.2pp | 34.9%-6.3pp | 41.2%+11.2pp | ||
| -$3.53B-203% | $3.42B-49.3% | $6.75B+34.9% | $5B-15.3% | $5.9B+41.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Merck & Co.'s revenue?
- Merck & Co. (MRK) generated $65.8B in revenue over the trailing twelve months, up 2.9% year over year.
- Is Merck & Co. profitable?
- Merck & Co. reported $8.9B in net income over the trailing twelve months, a 13.6% net margin.
- What is Merck & Co.'s earnings per share?
- Merck & Co.'s diluted EPS over the trailing twelve months is $3.56.
- Where does Merck & Co.'s income statement data come from?
- Every line is extracted from Merck & Co.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
